8 weeks versus 12 weeks of sofosbuvir–velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India
Source: View publication →
An 8-week regimen of sofosbuvir-velpatasvir was found to be non-inferior to the standard 12-week regimen in achieving sustained virological response (SVR12) for treatment-naive, non-cirrhotic patients with chronic hepatitis C.
Key Findings
Study Design
Study Limitations
Clinical Significance
This landmark non-inferiority trial establishes that treatment-naive patients without cirrhosis can be safely and effectively cured of HCV with just 8 weeks of pan-genotypic sofosbuvir-velpatasvir. This paradigm shift will reduce medication burden, increase patient compliance, and vastly improve cost-effectiveness—critical factors in scaling up global HCV elimination efforts in low- and middle-income countries.
Historical Context
The introduction of direct-acting antivirals (DAAs) transformed the landscape of hepatitis C management from highly toxic interferon-based therapies to highly effective, tolerable, all-oral pan-genotypic cures. While the standard course for sofosbuvir-velpatasvir was firmly established at 12 weeks, the high cost of DAA therapy remained a barrier to global HCV elimination goals. Although another pan-genotypic regimen (glecaprevir/pibrentasvir) received approval for an 8-week course, shortening the treatment duration of the highly accessible sofosbuvir-velpatasvir combination had not been proven in a large-scale RCT until the RESOLVE trial.
Guided Discussion
High-yield insights from every perspective
What are the mechanisms of action for sofosbuvir and velpatasvir, and why is combining them effective in treating hepatitis C across different genotypes?
Key Response
Sofosbuvir is an NS5B RNA-dependent RNA polymerase inhibitor, and velpatasvir is an NS5A inhibitor. Combining them targets multiple steps of the viral replication cycle, rapidly halting viral replication, preventing the emergence of resistance, and providing pan-genotypic efficacy. This is critical for simplifying treatment protocols without the need for prior genotyping.
When evaluating a patient for a shortened 8-week SOF/VEL regimen based on the RESOLVE trial, what specific clinical criteria must be strictly verified before initiation?
Key Response
Clinicians must ensure the patient is both treatment-naive and strictly non-cirrhotic. This requires careful assessment using non-invasive fibrosis scores like FIB-4 or transient elastography. Inadvertently giving a shortened regimen to a patient with unrecognized compensated cirrhosis could lead to treatment failure, virological relapse, and the development of resistance-associated substitutions.
How might the baseline prevalence of specific HCV genotypes, particularly genotype 3 which is highly prevalent in India, influence the interpretation of these results when considering the 8-week SOF/VEL regimen in other global populations?
Key Response
Genotype 3 is traditionally considered the most difficult to treat and has the highest prevalence in India. Demonstrating the non-inferiority of an 8-week regimen in a genotype 3-heavy population provides exceptionally robust evidence for its efficacy. Fellows must consider how this 'stress test' of the regimen translates to Western populations where genotypes 1 and 2 are more common, potentially offering even higher safety margins.
From a health equity and systems perspective, how does shortening the standard SOF/VEL regimen from 12 to 8 weeks alter our practical approach to achieving WHO HCV micro-elimination targets?
Key Response
An 8-week regimen reduces drug costs by roughly 33 percent and lowers the pill burden, which improves medication adherence and reduces loss to follow-up. This makes simplified, decentralized test-and-treat strategies highly viable in resource-limited and high-risk settings, allowing attendings to implement broader community treatment programs and scale up elimination efforts.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In evaluating the statistical design of the RESOLVE trial, what are the implications of the chosen non-inferiority margin, and how does the expected SVR12 rate dictate the required sample size?
Key Response
The choice of the non-inferiority margin (typically around -4% to -6% in modern HCV trials) is critical. Because modern DAAs have SVR12 rates exceeding 95%, researchers must select a tight margin to ensure a shorter regimen does not unacceptably compromise efficacy. This requires a sufficiently large sample size to power the study adequately, balancing the preservation of the treatment effect against practical public health benefits.
As a peer reviewer assessing this open-label, non-inferiority trial, what are the primary threats to validity regarding loss to follow-up, and how should the intention-to-treat (ITT) versus per-protocol (PP) analyses be weighted?
Key Response
In non-inferiority trials, an intention-to-treat analysis can paradoxically bias results toward non-inferiority (the null hypothesis of no difference) if there is significant loss to follow-up or poor protocol adherence in both arms. A rigorous reviewer would heavily scrutinize dropout rates and ensure the non-inferiority conclusion holds robustly in the per-protocol population to avoid publishing support for a truly inferior shortened regimen.
Based on the RESOLVE trial results, should current AASLD-IDSA and EASL guidelines be updated to recommend an 8-week SOF/VEL regimen as a first-line option for all treatment-naive, non-cirrhotic patients globally?
Key Response
Current guidelines recommend 12 weeks of SOF/VEL or 8 weeks of glecaprevir/pibrentasvir for this specific population. Recommending 8 weeks of SOF/VEL would harmonize the duration across all major pan-genotypic regimens. The committee must weigh whether a single-country open-label RCT provides a sufficient Level of Evidence to change the global standard of care, or if regional guidelines should adopt it first based on local genotype prevalence and cost considerations.
Clinical Landscape
Noteworthy Related Trials
ASTRAL-1 Trial
Tested
Sofosbuvir-velpatasvir for 12 weeks
Population
Patients with HCV genotype 1, 2, 4, 5, or 6
Comparator
Placebo
Endpoint
SVR12
ASTRAL-3 Trial
Tested
Sofosbuvir-velpatasvir for 12 weeks
Population
Patients with HCV genotype 3
Comparator
Sofosbuvir plus ribavirin for 24 weeks
Endpoint
SVR12
POLARIS-2 Trial
Tested
Sofosbuvir-velpatasvir-voxilaprevir for 8 weeks
Population
DAA-naive patients with HCV genotypes 1-6
Comparator
Sofosbuvir-velpatasvir for 12 weeks
Endpoint
SVR12
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis